<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00135551</url>
  </required_header>
  <id_info>
    <org_study_id>copeadministrator</org_study_id>
    <nct_id>NCT00135551</nct_id>
  </id_info>
  <brief_title>Benidipine-based Comparison of Angiotensin Receptors, β-blockers, or Thiazide Diuretics in Hypertensive Patients</brief_title>
  <acronym>COPE</acronym>
  <official_title>The Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seiji Umemoto, M.D., Ph.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Japanese Society of Hypertension</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yamaguchi University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyowa Hakko Kogyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>COPE Trial Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A number of major clinical trials have demonstrated the clinical benefits of lowering blood
      pressure and have indicated that a majority of patients with hypertension will require more
      than one drug to achieve optimal blood pressure control.

      There is little data showing which antihypertensive combination best protects patients from
      cardiovascular events and which best achieves the target blood pressure with the fewest
      adverse events.

      The COPE trial is planned to investigate, in patients with hypertension, which combination of
      the antihypertensive drugs, angiotensin receptor blockers, β-blockers or thiazide diuretics
      in addition to a long-acting calcium antagonist, benidipine hydrochloride, is superior to
      achieve the targeted blood pressure and prevent cardiovascular events with the fewest adverse
      drug effects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A composite of fatal and non-fatal cardiovascular events.</measure>
    <time_frame>first event</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Achievement of target blood pressure (&lt; 140 mmHg/90 mmHg).</measure>
    <time_frame>time course</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality.</measure>
    <time_frame>first event</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death from cardiovascular events.</measure>
    <time_frame>first event</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatal and non-fatal cardiovascular events.</measure>
    <time_frame>first event</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization due to heart failure.</measure>
    <time_frame>first event</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New onset of diabetes mellitus.</measure>
    <time_frame>first event</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (adverse events and adverse drug reaction).</measure>
    <time_frame>total number</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">3501</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>angiotensin receptor blockers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>benidipine+angiotensin receptor blockers, titlation scheme</description>
  </arm_group>
  <arm_group>
    <arm_group_label>β-blockers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>benidipie+β-blockers, titlation scheme</description>
  </arm_group>
  <arm_group>
    <arm_group_label>thiazide diuretics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>benidipine+thiazide diuretics, titlation scheme</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angiotensin receptor blockers</intervention_name>
    <description>benidipine+angiotensin receptor blocker, titlation scheme</description>
    <arm_group_label>angiotensin receptor blockers</arm_group_label>
    <other_name>benidipine, angiotensin receptor blockers</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>β-blockers</intervention_name>
    <description>benidipine+β-blockers, titlation scheme</description>
    <arm_group_label>β-blockers</arm_group_label>
    <other_name>benidipine, β-blockers</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiazide diuretics</intervention_name>
    <description>benidipie+thiazide diuretics, titlation scheme</description>
    <arm_group_label>thiazide diuretics</arm_group_label>
    <other_name>benidipie, thiazide diuretics</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients who are required a combination therapy with sitting systolic blood
             pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg.

          -  Outpatients aged over 40 years and less than 85 years (inclusive), regardless of sex.

          -  Previously untreated patients or patients who are on other therapy, which can be
             converted to 4mg of benidipine.

          -  Patients who can be treated with benidipine, angiotensin receptor blockers,
             β-blockers, and thiazide diuretics.

        Exclusion Criteria:

          -  Seated systolic blood pressure ≥ 200 mmHg or seated diastolic blood pressure ≥ 120
             mmHg.

          -  Secondary hypertension.

          -  Type I diabetes mellitus or type 2 diabetes on insulin treatment.

          -  History of cerebrovascular disorder, myocardial infarction, angina pectoris, coronary
             angioplasty or coronary artery bypass graft surgery within 6 months prior to enrolment
             in the study.

          -  Heart failure (New York Heart Association [NYHA] functional classification II, III or
             IV).

          -  Chronic atrial fibrillation or atrial flutter.

          -  Congenital heart disease or a history of rheumatic heart disease.

          -  Severe peripheral arterial disease (Fontaine Class II, III or IV).

          -  Serious liver dysfunction (AST or ALT ≥100 IU / l).

          -  Serious renal dysfunction (serum creatinine ≥ 2mg/dl).

          -  History of malignancy 5 years prior to study entry.

          -  Pregnancy.

          -  Compliance rate &lt; 70% assessed by a patient interview.

          -  Known hypersensitivity or contraindication to benidipine, angiotensin receptor
             blockers, β-blockers, and thiazide diuretics.

          -  Other serious illness or significant abnormalities that the investigator judges
             inappropriate for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toshio Ogihara, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Geriatric Medicine, Osaka University Graduate School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Takao Saruta, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Internal Medicine, Keio University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine</name>
      <address>
        <city>Ube</city>
        <state>Yamaguchi</state>
        <zip>755-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://ds.cc.yamaguchi-u.ac.jp/~cope/</url>
    <description>Click here for more information about this study (in Japanese): The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial</description>
  </link>
  <link>
    <url>http://www.jpnsh.org/index_e.html</url>
    <description>Japanese Society of Hypertension</description>
  </link>
  <link>
    <url>http://ds.cc.yamaguchi-u.ac.jp/~ninai/</url>
    <description>Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine</description>
  </link>
  <link>
    <url>http://www.med.osaka-u.ac.jp/pub/geriat/www/</url>
    <description>Department of Geriatric Medicine, Osaka University Graduate School of Medicine</description>
  </link>
  <reference>
    <citation>Ogihara T, Matsuzaki M, Matsuoka H, Shimamoto K, Shimada K, Rakugi H, Umemoto S, Kamiya A, Suzuki N, Kumagai H, Ohashi Y, Takishita S, Abe K, Saruta T; COPE Trial Group. The combination therapy of hypertension to prevent cardiovascular events (COPE) trial: rationale and design. Hypertens Res. 2005 Apr;28(4):331-8. Review.</citation>
    <PMID>16138563</PMID>
  </reference>
  <results_reference>
    <citation>Matsuzaki M, Ogihara T, Umemoto S, Rakugi H, Matsuoka H, Shimada K, Abe K, Suzuki N, Eto T, Higaki J, Ito S, Kamiya A, Kikuchi K, Suzuki H, Tei C, Ohashi Y, Saruta T; Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens. 2011 Aug;29(8):1649-59. doi: 10.1097/HJH.0b013e328348345d.</citation>
    <PMID>21610513</PMID>
  </results_reference>
  <results_reference>
    <citation>Ogihara T, Matsuzaki M, Umemoto S, Rakugi H, Matsuoka H, Shimada K, Higaki J, Ito S, Kamiya A, Suzuki H, Ohashi Y, Shimamoto K, Saruta T; Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Combination therapy for hypertension in the elderly: a sub-analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial. Hypertens Res. 2012 Apr;35(4):441-8. doi: 10.1038/hr.2011.216. Epub 2012 Jan 26.</citation>
    <PMID>22278623</PMID>
  </results_reference>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2005</study_first_submitted>
  <study_first_submitted_qc>August 24, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2005</study_first_posted>
  <last_update_submitted>February 19, 2012</last_update_submitted>
  <last_update_submitted_qc>February 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>COPE Trial Group</investigator_affiliation>
    <investigator_full_name>Seiji Umemoto, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Multicenter clinical trial</keyword>
  <keyword>PROBE</keyword>
  <keyword>Combination therapy</keyword>
  <keyword>Benidipine</keyword>
  <keyword>Essential Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
    <mesh_term>Sodium Chloride Symporter Inhibitors</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Benidipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

